Dr Reddy's launches generic anti-bacterial drug in US

The company's product is a therapeutic generic equivalent of Oracea capsules (40 mg) approved by the US Food and Drug Administration (USFDA).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EiNp5cI
via IFTTT

Read More

Covishield maker AstraZeneca, SII, govt all responsible for my daughter's death: Father to file case along with 8 parents

In a heartbreaking turn of events, the parents of Karunya, who tragically passed away in 2021 after allegedly receiving the Covishield vaccine, are seeking legal recourse. Her grieving father, Venugopalan Govindan, blames multiple parties for his daughter's death and is determined to hold them accountable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1QXknA0
via IFTTT

Read More

Quadria cap picks up minority stake in NephroPlus

NephroPlus, India's largest dialysis chain, has secured $103 million (₹860 crore) in a Series F funding round led by Quadria Capital. This funding, a mix of fresh capital and a secondary sale, aims to drive expansion plans within India and targeted markets overseas. The primary component of the funding is ₹100 crore. Quadria Capital will become a minority shareholder, valuing NephroPlus at over ₹2,000 crore. Existing investors like Bessemer Venture Partners, International Finance Corporation, and IIFL also participated in the funding round, reducing their stakes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NTviftP
via IFTTT

Read More

Bayer acquires remaining 25% stake in Bayer Zydus Pharma Pvt Ltd to secure full ownership

Bayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited have concluded their joint venture, Bayer Zydus Pharma Private Limited (BZPPL), established in 2011 for pharmaceutical sales and marketing in India. Bayer is now acquiring full ownership of the entity as per pre-agreed terms. The joint venture successfully combined Zydus's Indian marketing expertise and distribution network with Bayer's global innovation, making strides in various therapeutic areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LtSw9Rn
via IFTTT

Read More

Maiva Pharma raises Rs 1,000 cr from Morgan Stanley PE and India Life Sciences Fund

Maiva Pharma has raised Rs 1,000 crore from Morgan Stanley Private Equity Asia and India Life Sciences Fund, including both primary and secondary funding. The funds will be used to set up a new manufacturing facility near Karnataka's Hosur, with capabilities in sterile dosage forms, including pre-filled syringes, bags, oncology, and hormonal injectables. Maiva's complex injectables development and manufacturing capability, strong compliance and regulatory standards, and transparency differentiate the company from competitors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GW2Lu4P
via IFTTT

Read More

Maiva Pharma raises Rs 1000 crore from Morgan Stanley Private Equity, InvAscent

Morgan Stanley PE Asia and India Life Sciences Fund are investing almost equally, total stake with both funds combined will be over 60% post primary investment, the company told ET.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IcyfZqM
via IFTTT

Read More

Took AstraZeneca's Covishield? Should I be worried? What are the risky side effects I shouldn't ignore? Here are all the answers

AstraZeneca's admission of Covishield's potential link to Thrombosis with Thrombocytopenia Syndrome (TTS) has stirred concerns. Despite its rarity, social media debates over vaccine safety persist. Covishield, similar to AstraZeneca's, faces scrutiny, though TTS isn't exclusive to them. Here are all the answers about your doubts related to the recent controversy over AstraZeneca's Covishield.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gPAIL8N
via IFTTT

Read More